NCT02081300View on ClinicalTrials.gov

Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism

PHASE3CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Male Hypogonadism
Interventions
DRUG

Oral testosterone undecanoate, LPCN 1021

DRUG

Topical testosterone gel 1.62 %

Sponsors

Lead Sponsor

Lipocine Inc.
All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

PPD Development, LP

INDUSTRY

lead

Lipocine Inc.

INDUSTRY